Pfizer Inc PFE

$28.47 -0.39 (-1.35%)

Valuation

Market cap
164,497,792,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.47
P/E (forward)
9.49
Profit margin
12.42%
Debt to equity
0.70

Trading

Volume
35,356,500
Avg volume
33,489,727
Day's range
$28.35 – $28.67
Shares out
5,699,854,000
Stochastic %K
4%
Beta
0.31
Analysts
Hold
Price target
$30.56

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

framus_morrigan Nov 18, 8:05 AM
$PFE Zoom in. HS pattern breakdown + rising wedge breakdown in progress? ... 50% fibo retracement =$ 26's , looks a reasonable first target after that 35% in 2 months. Let's see ... Daily candles chart.
0 replies
LLLJJJ Nov 18, 2:17 AM
$HDV $PFE Sell all AI stocks and gradually buy into reliable dividend stocks for peace of mind.😆
0 replies
stevemano Nov 18, 1:47 AM
$MNKD $PFE $SNY Get it done!
0 replies
TraderMike69 Nov 17, 9:19 PM 0 replies
MrPeanutEsquire Nov 17, 8:52 PM
$PFE Tech is not used to being Pfizer. They have been Pfizered for only a month now and are crying. We have to be Pfizer every day, they know nothing of pain and annoyance
2 replies
graywolf Nov 17, 8:38 PM
$SLS This won’t stay independent for too long imo. $JNJ $PFE $LLY or $MRK shouls make a move!
1 replies
BarkingPuppy Nov 17, 7:58 PM
$ELTP $PFE $JNJ $MRNA Here We Go Elite Pharmaceuticals !!!!
0 replies
shopno Nov 17, 7:50 PM
$MRK $RVMD $SLS Merck’s offer was real (don’t ask how I know if). SLS will make a record BO with GPS + 009 + WT1. More importantly the patents expirations timing, including $MRK keytruda ($32 billions / year), $BMS.X opdivo ($10 billions / year), $PFE Ibrance ($5 billions / year), and others.
1 replies